Clinical validity of proliferating cell nuclear antigen as an objective marker for evaluating biologic features in patients with untreated prostate cancer

Background:  Although Gleason grading may be the most useful system for evaluating biological activity of untreated prostate cancer, lack of interobserver validity with Gleason scores (GS) is an unsolved issue. In this study, the proliferating cell nuclear antigen labeling index (PCNA LI) in untreated prostate cancer was investigated in order to clarify the usefulness of supplemental and objective markers for evaluating the biologic features of prostate cancer.

[1]  B. Szende,et al.  Repeated biopsies in evaluation of therapeutic effects in prostate carcinoma , 2001, The Prostate.

[2]  J. Isaacs,et al.  The biology of hormone refractory prostate cancer. Why does it develop? , 1999, The Urologic clinics of North America.

[3]  V. Reuter.  Pathological changes in benign and malignant prostatic tissue following androgen deprivation therapy. , 1997, Urology.

[4]  B. Helpap.  Cell kinetic studies on prostatic intraepithelial neoplasia (PIN) and atypical adenomatous hyperplasia (AAH) of the prostate. , 1995, Pathology, research and practice.

[5]  P. Carroll,et al.  Cellular proliferation in prostatic adenocarcinoma as assessed by bromodeoxyuridine uptake and Ki‐67 and PCNA expression , 1995, The Prostate.

[6]  T. Iwaki,et al.  Hydrated autoclave pretreatment enhances tau immunoreactivity in formalin-fixed normal and Alzheimer's disease brain tissues. , 1991, Laboratory investigation; a journal of technical methods and pathology.

[7]  M. Harada,et al.  Immunocytochemical demonstration of S phase cells by anti-bromodeoxyuridine monoclonal antibody in human prostate adenocarcinoma. , 1989, The Journal of urology.

[8]  F. Dean,et al.  An inhibitor of the in vitro elongation reaction of simian virus 40 DNA replication is overcome by proliferating-cell nuclear antigen. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[9]  R. Bravo,et al.  Cyclin/PCNA is the auxiliary protein of DNA polymerase-δ , 1987, Nature.

[10]  M. Harper,et al.  Cell proliferation in prostatic carcinoma: comparative analysis of Ki-67, MIB-1 and PCNA , 2004, The Histochemical Journal.

[11]  M. Kattan,et al.  Assessment of the biologic markers p53, ki‐67, and apoptotic index as predictive indicators of prostate carcinoma recurrence after surgery , 1998 .

[12]  M. Kattan,et al.  Assessment of the biologic markers p53, Ki-67, and apoptotic index as predictive indicators of prostate carcinoma recurrence after surgery. , 1998, Cancer.

[13]  J. Kumazawa,et al.  Proliferating cell nuclear antigen in needle biopsy specimens of prostatic carcinoma. , 1994, European urology.

[14]  K. Griffiths,et al.  Relationship of proliferating cell nuclear antigen (PCNA) in prostatic carcinomas to various clinical parameters , 1992, The Prostate.